ACS AUTHORCHOICE



# Allylic–Allylic Alkylation with 3,5-Dimethyl-4-nitroisoxazole: A Route to Dicarboxylic Acid Derivatives

Dorota Kowalczyk-Dworak, Marcin Kwit, and Łukasz Albrecht\*



# INTRODUCTION

derivatives.

The asymmetric synthesis of simple, chiral building blocks possessing important functional groups (that can be subsequently utilized for their further chemical and stereochemical diversifications) constitutes an important task in the contemporary organic synthesis.<sup>1</sup> Carboxylic acids and their  $\alpha,\beta$ -unsaturated derivatives belong to such a category of compounds with widespread applications in organic and polymer sciences (Scheme 1).<sup>2</sup> Dicarboxylic acids bearing

# Scheme 1. Importance of Carboxylic Acids and Their Derivatives



two carboxylic moieties in their structure are an interesting group of carboxylic acid derivatives with molecules containing such a structural motif being exploited in target-oriented synthesis.<sup>3</sup>

Allylic alkylation with the participation of Morita–Baylis– Hillman (MBH) carbonates realized under nucleophilic catalysis constitutes a facile route for the synthesis of acrylic acid derivatives bearing a chiral substituent in the  $\alpha$ -position.<sup>4</sup> The synthetic potential of allylic alkylations realized with MBH-carbonates has been recently significantly expanded by employing various vinylogous pronucleophiles in this reaction.<sup>5</sup> In such a manner, allylic–allylic alkylations have been introduced, leading to various synthetically relevant products bearing two allylic moieties connected through the C–C bond in a stereocontrolled manner.

Important precursors of dicarboxylic acids

In continuation of our studies related to the development of novel vinylogous reactivities,<sup>6,7</sup> we became particularly interested in 3,5-dimethyl-4-nitroisoxazole (1, Scheme 2). This compound and its alkylidene derivatives have recently emerged as a useful class of compounds capable of participating in various C-C bond forming reactions.<sup>8</sup> One relevant feature of this group of reactants is the possibility to transform the isoxazole ring system to the carboxylic acid group. As a consequence, they are considered as carboxylic acid surrogates. To our surprise, such pronucleophiles have never before been explored in the allylic-allylic alkylation with MBH-carbonates 2 realized under nucleophilic catalysis conditions (Scheme 2, top). It was anticipated that the initially obtained product 3 could be utilized as a direct precursor of dicarboxylate 4. Notably, an alternative strategy for the preparation of 4 can be based on the allylic alkylation of MBH-carbonates with malonates or related systems, followed by the hydrolysis and monodecarboxylation. While the first step of the sequence is known in the literature, the development of the enantioselective protocol remains a challenge or requires a specific substitution pattern.<sup>9</sup> Therefore, the development of an alternative strategy is highly appealing.

Received: September 17, 2019 Published: February 10, 2020



Scheme 2. Synthetic Objectives of Our Study and the Anticipated Mechanistic Scenario



Herein, we present our studies on the development of the first allylic-allylic alkylation using 3.5-dimethyl-4-nitroisoxazole (1) as a vinylogous pronucleophile and the application of the products 3 obtained for the synthesis of enantiomerically enriched dicarboxylates 4. The anticipated mechanistic scenario for the key step of the devised strategy should be initiated through two independent activation processes (Scheme 2, bottom). The first one involving the corresponding MBH-carbonate 2 relies on the  $S_N 2'$  reaction of 2 with a nucleophilic catalyst to give intermediate A. The reaction proceeds with the concomitant release of carbon dioxide and tert-butoxide anion. In a parallel transformation 3,5-dimethyl-4-nitroisoxazole (1) is deprotonated to give anion B that is stabilized through mesomeric effect. A subsequent second S<sub>N</sub>2' reaction between A and B yields target product 3 and releases the nucleophilic catalyst that can re-enter the catalytic cycle.

#### RESULTS AND DISCUSSION

The optimization studies were performed using isoxazole 1 and MBH-carbonate 2a as model reactants (Table 1 and Supporting Information). Initially, quinine 5a was used as a catalyst, and to our delight, the formation of the desired product 3a was observed (Table 1, entry 1). However, both the yield and enantioselectivity of the reaction were low. Therefore, a catalyst screening was performed employing various cinchona-alkaloids-derived systems 5b-g. While cupreine derivative 5b catalyzed the reaction with similar efficiency (Table 1, entry 2), the thiourea derivative 5c failed to induce any reactivity (Table 1, entry 3). Therefore, we turned our attention to dimeric catalysts 5d-g (Table 1, entries 4-7) as their ability to act as nucleophilic catalysts in allylic alkylation reactions is well recognized. We were pleased to observe that the use of 5f led to an increase in enantioselectivity of the developed reaction (Table 1, entry 6). In order to further improve the results, the solvent screening was initiated (Table 1, entries 6, 8-12). Among solvents tested, chloroform proved the best reaction medium that enabled to increase the yield of the reaction significantly

 Table 1. Enantioselective Allylic–allylic Alkylation Using

 3,5-Dimethyl-4-nitroisoxazole 1 as a Vinylogous

 Pronucleophile: Optimization Studies<sup>a</sup>



<sup>*a*</sup>Reactions performed on a 0.1 mmol scale using 1 (1 equiv) and 2a (1 equiv) in 0.4 mL of the solvent. <sup>*b*</sup>Isolated yields are given. <sup>*c*</sup>Determined by a chiral stationary phase HPLC. <sup>*d*</sup>Reaction was performed in 0.8 mL of CH<sub>2</sub>Cl<sub>2</sub>. <sup>*c*</sup>Reaction was performed in 0.2 mL of CH<sub>2</sub>Cl<sub>2</sub>. <sup>*f*</sup>Reaction was performed using 1 (1.5 equiv). <sup>*g*</sup>Reaction was performed using 2a (1.5 equiv).

(Table 1, entry 8). In the course of further studies, various experiments aiming at fine-tuning of the reaction conditions were performed (Table 1, entries 13-19). It was found that neither dilution of the reaction mixture (Table 1, entry 13) nor an increase in concentration (Table 1, entry 14) had a beneficial effect on its outcome. Subsequently, the temperature effect was checked (Table 1, entries 8, 15–17). Interestingly, while the decrease in temperature resulted in sluggish conversion (Table 1, entry 15), its increase led to an

improvement of reactivity (Table 1, entries 16 and 17) with 40 °C, providing also a better outcome in terms of enantioselectivity of the process (Table 1, entry 16). Finally, the influence of the relative reactant ratios was checked; however, it resulted in deteriorated results (Table 1, entries 18 and 19).

With the optimization studies accomplished (Table 1, entry 16), the scope of the developed methodology was studied (Table 2). It was found that the presence of electron-

Table 2. Enantioselective Allylic–Allylic Alkylation Using3,5-Dimethyl-4-nitroisoxazole 1 as a VinylogousPronucleophile: Scope Studies<sup>a</sup>



<sup>*a*</sup>Reactions performed on a 0.1 mmol scale using 1 (1 equiv) and 2a (1 equiv) in 0.4 mL of the solvent. <sup>*b*</sup>Isolated yields are given. <sup>*c*</sup>Determined by a chiral stationary phase HPLC. <sup>*d*</sup>Reaction was performed on a 5 mmol scale.

withdrawing groups on the aromatic ring in 2 did not significantly influence the reaction outcome (Table 2, entries 2-6). In all of the cases, high yields and enantioselectivities were obtained. Similarly, the reaction proved unbiased toward the position of substituent with para-, meta- and orthosubstitution being well-tolerated (Table 2, entries 4-6). Furthermore, it was found that the introduction of electrondonating groups had no deteriorative effect on the reaction (Table 2, entries 7 and 8). The disubstituted aromatic ring, heteroaromatic group, and alkenyl moiety were also able to be present in 2 as demonstrated in the synthesis of 3i-k (Table 2, entries 9-11). Finally, the possibility to modify the ester group in 2 was checked (Table 2, entries 12 and 13) with excellent enantiocontrol achieved when tert-butyl ester was employed (Table 2, entry 13). The reaction also proved possible to scale up (5 mmol, Table 1, entry 14) with 3a obtained in lower yield (54%) (for information on additional scope experiments, see Supporting Information).

The absolute configuration of the representative products **3a**,**g** was established by comparison of their experimental

pubs.acs.org/joc

electronic circular dichroism (ECD) spectrum with the calculated ones (for details, see Supporting Information).<sup>10</sup> A perfect consistency between experimental and theoretical data (see Figure 1) unambiguously confirmed the *R* absolute configuration of the model compounds tested. The absolute stereochemistry of the products  $3b-f_{,h}-m$  was assigned through analogy.



**Figure 1.** ECD spectra of **3a** and **3g**, measured in cyclohexane (solid black lines) and calculated at the TD-CAM-B3LYP/6-311++G-(2d,2p) level and  $\Delta\Delta G$ -based Boltzmann average (dashed blue lines). Wavelengths were corrected to match the experimental UV maximum.

In order to demonstrate the synthetic usefulness of the allylic–allylic alkylation products 3, acrylate 3a was subjected to selected transformations (Scheme 3). Initially, the possibility to transform the 4-nitroisoxazole moiety in 3a into the carboxylic group was attempted (Scheme 3, top). It

Scheme 3. Enantioselective Allylic–Allylic Alkylation Using 3,5-Dimethyl-4-nitroisoxazole 1 as a Vinylogous Pronucleophile: Synthetic Applications



proved possible employing sodium hydroxide aqueous solution. The dicarboxylic acid initially obtained was directly subjected to esterification to afford dimethyl ester **4a** in an 83% yield. Importantly, the optical purity introduced in the organocatalytic step was almost entirely maintained despite basic reaction conditions. In the course of further studies, it was found that the reduction of the nitro group in **3a** was possible to be conducted chemoselectively when Zn in acetic acid was used as a reducing agent (Scheme 3, bottom). The reaction again occurred with the preservation of the optical purity of **3a**.

#### CONCLUSIONS

In conclusion, we have demonstrated that 3,5-dimethyl-4nitroisoxazole 1 serves as a new vinylogous pronucleophile in the allylic–allylic alkylation reaction. The reaction proceeded efficiently in the presence of dimeric cinchona alkaloid derivative **5f** as the nucleophilic catalyst initiating the reaction sequence. Target products bearing an interesting functionalization potential were obtained with high yields and with excellent enantiocontrol. The possibility to transform the 4nitroisoxazole moiety into the carboxylic group was demonstrated.

#### EXPERIMENTAL SECTION

**General Information.** Unless otherwise noted, analytical grade solvents and commercially available reagents were used without further purification. NMR spectra were acquired on a Bruker Ultra Shield 700 instrument, running at 700 MHz for <sup>1</sup>H and 176 MHz for <sup>13</sup>C, respectively. Chemical shifts ( $\delta$ ) are reported in ppm relative to residual solvent signals (CDCl<sub>3</sub>: 7.26 ppm for <sup>1</sup>H NMR, 77.16 ppm for <sup>13</sup>C NMR). Mass spectra were recorded on a Bruker Maxis Impact spectrometer using electrospray (ES+) ionization (referenced to the mass of the charged species). Analytical thin-layer chromatography (TLC) was performed using precoated aluminum-backed plates (Merck Kieselgel 60 F254) and visualized by ultraviolet irradiation. Silica gel (Silica gel 60, 230–400 mesh, Fluka) was used for flash chromatography (FC). MBH carbonates **2** were prepared according to literature procedures.<sup>11</sup> Cinchona-alkaloid-derived catalyst **5c** was synthesized following the literature procedure.<sup>12</sup>

General Procedure for the Synthesis of Compounds 3a-m. An ordinary screw-cap vial was charged with a magnetic stir bar, the corresponding 3,5-dimethyl-4-nitroisoxazole 1 (0.1 mmol, 1 equiv), the corresponding MBH carbonate 2 (0.1 mmol, 1 equiv), catalyst Sf (0.01 mmol, 0.1 equiv), and CHCl<sub>3</sub> (0.4 mL). The reaction mixture was stirred at 40 °C in an aluminum heating block and monitored by <sup>1</sup>H NMR spectroscopy. After 24 h, the mixture was directly purified by FC on silica gel to afford a target product 3.

(*R*)-Methyl 4-(3-Methyl-4-nitroisoxazol-5-yl)-2-methylene-3-phenylbutanoate (**3a**). Following the general procedure, **3a** was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 84% yield (28.5 mg) as a pale-yellow oil (910.4 mg, 58% yield of **3a** was obtained when the reaction was performed on a 5 mmol scale). <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.32–7.28 (m, 2H), 7.27–7.22 (m, 3H), 6.41 (s, 1H), 5.79 (d, *J* = 1.4 Hz, 1H), 4.60 (t, *J* = 8.1 Hz, 1H), 3.80–3.77 (m, 2H), 3.71 (s, 3H), 2.52 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.8, 166.5, 155.6, 141.5, 139.9, 129.6, 128.9 (2C), 127.8 (2C), 127.6, 125.8, 52.2, 44.1, 32.4, 11.7. HRMS (ESI-TOF) *m/z*: [M + Na]<sup>+</sup> calcd for C<sub>16</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>Na, 339.0952; found, 339.0951. The er was determined by HPLC using a Chiralpak IG column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major} = 11.6$  min,  $\tau_{minor} = 10.5$  min (96:4 er). [ $\alpha$ ]<sub>20</sub><sup>20</sup> -173.1 (*c* = 0.8, CHCl<sub>3</sub>).

(R)-Methyl 4-(3-Methyl-4-nitroisoxazol-5-yl)-2-methylene-3-(4-(trifluoromethyl)phenyl)-butanoate (**3b**). Following the general procedure, **3b** was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 82% yield (33.4 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.41 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 6.40 (s, 1H), 5.77 (d, *J* = 1.2 Hz, 1H), 4.54 (td, *J* = 8.2, 1.2 Hz, 1H), 3.74 (d, *J* = 8.1 Hz, 2H), 3.69 (s, 3H), 2.51 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>): δ 172.2, 166.1, 155.8, 144.1, 140.1, 130.2 (q, *J* = 30.7 Hz), 128.2 (2C), 128.0, 126.4, 125.9 (q, *J* = 3.7 Hz, 2C), 125.5, 124.1 (q, *J* = 272.1 Hz), 52.4, 43.9, 32.1, 11.7. HRMS (ESI-TOF) *m*/ *z*: [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>Na, 407.0826; found, 407.0828. The er was determined by HPLC using a Chiralpak IG column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 8.8 min,  $\tau_{minor}$  = 11.5 min (90:10 er). [ $\alpha$ ]<sup>20</sup><sub>D</sub> - 146.8 (*c* = 0.7, CHCl<sub>3</sub>).

(*R*)-Methyl 3-(4-Bromophenyl)-4-(3-methyl-4-nitroisoxazol-5-yl)-2-methylenebutanoate (3c). Following the general procedure, 3c was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 86% yield (35.9 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$ 7.41 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 6.40 (s, 1H), 5.77 (d, J = 1.3 Hz, 1H), 4.55–4.53 (m, 1H), 3.74 (d, J = 8.1 Hz, 2H), 3.69 (s, 3H), 2.51 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$ 172.4, 166.3, 155.7, 141.1, 139.0, 132.0 (2C), 129.6 (2C), 126.0 (2C), 121.6, 52.3, 43.6, 32.2, 11.8. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> calcd for C<sub>16</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>5</sub>Na, 417.0057/419.0037; found, 417.0069/419.0044. The er was determined by HPLC using a Chiralpak IF column [hexane/iPrOH (80:20)]; flow rate 1.0 mL/ min;  $\tau_{major}$  = 18.0 min,  $\tau_{minor}$  = 15.9 min (97:3 er). [ $\alpha$ ]<sup>20</sup><sub>D</sub> –151.2 (c = 0.9, CHCl<sub>3</sub>).

(*R*)-Methyl 3-(4-Chlorophenyl)-4-(3-methyl-4-nitroisoxazol-5-yl)-2-methylenebutanoate (**3d**). Following the general procedure, **3d** was isolated by FC on silica (hexane/ethyl acetate 96:4) in a 90% yield (33.6 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.26–7.25 (m, 2H), 7.18 (d, *J* = 8.5 Hz, 2H), 6.40 (s, 1H), 5.77 (d, *J* = 1.2 Hz, 1H), 4.61–4.47 (m, 1H), 3.74 (d, *J* = 8.1 Hz, 2H), 3.69 (s, 3H), 2.51 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.4, 166.3, 155.7, 141.2, 138.5, 133.5, 129.2 (2C), 129.1 (2C), 126.0 (2C), 52.3, 43.6, 32.3, 11.8. HRMS (ESI-TOF) *m/z*: [M + Na]<sup>+</sup> calcd for C<sub>16</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>5</sub>Na, 373.0562; found, 373.0570. The er was determined by HPLC using a Chiralpak IG column [hexane/iPrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 14.6 min,  $\tau_{minor}$  = 11.8 min (98:2 er). [ $\alpha$ ]<sup>2D</sup><sub>2</sub> –132.1 (*c* = 0.8, CHCl<sub>3</sub>).

(*R*)-*Methyl* 3-(3-*Chlorophenyl*)-4-(3-*methyl*-4-*nitroisoxazol*-5-*yl*)-2-*methylenebutanoate* (*3e*). Following the general procedure, **3e** was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 89% yield (33.2 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.24–7.20 (m, 3H), 7.14 (dt, *J* = 7.3, 1.8 Hz, 1H), 6.42 (s, 1H), 5.79 (d, *J* = 1.2 Hz, 1H), 4.55 (td, *J* = 8.2, 1.1 Hz, 1H), 3.77 (dd, *J* = 15.1, 8.1 Hz, 1H), 3.73 (dd, *J* = 15.1, 8.2 Hz, 1H), 3.70 (s, 3H), 2.52 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.3, 166.2, 155.7, 142.1, 140.8, 134.7, 130.2, 129.6, 128.0, 127.9, 126.3, 126.1, 52.4, 43.8, 32.3, 11.8. HRMS (ESI-TOF) *m*/*z*: [M + Na]<sup>+</sup> calcd for C<sub>16</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>5</sub>Na, 373.0562; found, 373.0566. The er was determined by HPLC using a Chiralpak IF column [hexane/*i*PrOH (80:20)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 7.6 min,  $\tau_{minor}$  = 6.8 min (96:4 er). [ $\alpha$ ]<sup>20</sup> –142.3 (*c* = 0.7, CHCl<sub>3</sub>).

(*S*)-*Methyl* 3-(2-*Chlorophenyl*)-4-(3-*methyl*-4-*nitroisoxazol*-5-*yl*)-2-*methylenebutanoate* (**3f**). Following the general procedure, **3f** was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 83% yield (30.1 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.34 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.30 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.24 (td, *J* = 7.6, 1.4 Hz, 1H), 7.18 (td, *J* = 7.6, 1.7 Hz, 1H), 6.45 (s, 1H), 5.71 (d, *J* = 1.4 Hz, 1H), 5.17–5.03 (m, 1H), 3.82 (dd, *J* = 15.1, 7.7 Hz, 1H), 3.69 (s, 3H), 3.67 (dd, *J* = 15.1, 8.3 Hz, 1H), 2.52 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.3, 166.3, 155.7, 140.6, 137.5, 134.3, 130.2, 129.6, 128.8, 128.4, 127.3, 126.8, 52.3, 40.4, 31.7, 11.8. HRMS (ESI-TOF) *m/z*: [M + Na]<sup>+</sup> calcd for C<sub>16</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>5</sub>Na, 373.0562; found, 373.0569. The er was determined by HPLC using a Chiralpak IC column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 11.0 min,  $\tau_{minor}$  = 10.3 min (94:6 er). [ $\alpha$ ]<sup>2D</sup><sub>2</sub> –129.5 (*c* = 0.8, CHCl<sub>3</sub>).

(*R*)-Methyl 4-(3-Methyl-4-nitroisoxazol-5-yl)-2-methylene-3-(p-tolyl)butanoate (**3g**). Following the general procedure, **3g** was isolated by FC on silica (hexane/ethyl acetate 96:4) in a 92% yield (32.5 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.12 (d, *J* = 8.1 Hz, 2H), 7.08 (d, *J* = 8.0 Hz, 2H), 6.36 (s, 1H), 5.75 (d, *J* = 1.2 Hz, 1H), 4.54 (t, *J* = 8.1 Hz, 1H), 3.74 (dd, *J* = 8.1, 1.5 Hz, 2H),

3.69 (s, 3H), 2.50 (s, 3H), 2.29 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  173.0, 166.6, 155.6, 141.7, 137.2, 136.9, 129.6, 129.5, 127.7, 127.6, 125.8, 125.5, 52.3, 43.7, 32.5, 21.3, 11.8. HRMS (ESI-TOF) *m*/*z*: [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>5</sub>Na, 353.1108; found, 353.1112. The er was determined by HPLC using a Chiralpak IG column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major} = 12.8$  min,  $\tau_{minor} = 11.2$  min (97:3 er). [ $\alpha$ ]<sup>20</sup> – 186.8 (c = 0.8, CHCl<sub>3</sub>).

(*R*)-*Methyl* 3-(4-*Methoxyphenyl*)-4-(3-*methyl*-4-*nitroisoxazo*)-5yl)-2-*methylenebutanoate* (3*h*). Following the general procedure, 3h was isolated by FC on silica (hexane/ethyl acetate 96:4) in a 90% yield (33.2 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$ 7.14 (d, *J* = 8.7 Hz, 2H), 6.81 (d, *J* = 8.7 Hz, 2H), 6.35 (s, 1H), 5.74 (d, *J* = 1.2 Hz, 1H), 4.53 (td, *J* = 8.2, 1.2 Hz, 1H), 3.77 (s, 3H), 3.73 (dd, *J* = 8.1, 2.5 Hz, 2H), 3.69 (s, 3H), 2.50 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  173.1, 166.7, 159.0, 155.7, 141.9, 132.0, 129.0 (2C), 125.5 (2C), 114.3 (2C), 55.5, 52.3, 43.5, 32.7, 11.9. HRMS (ESI-TOF) *m*/*z*: [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>Na, 369.1057; found, 369.1054. The er was determined by HPLC using a Chiralpak IG column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major} =$ 20.3 min,  $\tau_{minor} =$  18.9 min (96:4 er). [ $\alpha$ ]<sup>D</sup><sub>D</sub> –172.6 (*c* = 0.7, CHCl<sub>3</sub>).

(*R*)-Methyl 3-(Benzo[d][1,3]dioxol-5-yl)-4-(3-methyl-4-nitroisoxazol-5-yl)-2-methylenebutanoate (**3**i). Following the general procedure, **3**i was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 89% yield (34.1 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  6.72–6.69 (m, 2H), 6.68 (dd, J = 8.0, 1.7 Hz, 1H), 6.37 (s, 1H), 5.92 (s, 2H), 5.75 (d, J = 1.3 Hz, 1H), 4.50 (td, J = 8.2, 1.4 Hz, 1H), 3.71 (d, J = 1.2 Hz, 1H), 3.70 (s, 3H), 3.70 (d, J = 1.6 Hz, 1H), 2.51 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.8, 166.5, 155.7, 148.0, 147.0, 141.6, 133.7, 129.6, 125.4, 121.1, 108.5, 108.2, 101.3, 52.3, 43.7, 32.6, 11.8. HRMS (ESI-TOF) *m*/*z*: [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>7</sub>Na, 383.0850; found, 383.0855. The er was determined by HPLC using a Chiralpak IG column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 14.6 min,  $\tau_{minor}$  = 17.0 min (96:4 er). [ $\alpha$ ]<sub>20</sub><sup>20</sup> -146.3 (*c* = 0.7, CHCl<sub>3</sub>).

(S)-Methyl 3-(Furan-2-yl)-4-(3-methyl-4-nitroisoxazol-5-yl)-2methylenebutanoate (**3***j*). Following the general procedure, **3***j* was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 84% yield (27.6 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.32 (dd, *J* = 1.8, 0.8 Hz, 1H), 6.39 (s, 1H), 6.28 (dd, *J* = 3.2, 1.8 Hz, 1H), 6.13 (dt, *J* = 3.1, 0.8 Hz, 1H), 5.74 (d, *J* = 1.0 Hz, 1H), 4.72–4.61 (m, 1H), 3.83 (dd, *J* = 15.0, 8.5 Hz, 1H), 3.76 (s, 3H), 3.73 (dd, *J* = 15.0, 7.3 Hz, 1H), 2.53 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.3, 166.3, 155.7, 153.0, 142.4, 139.3, 127.7, 110.6 (2C), 107.1, 52.4, 38.2, 31.1, 11.8. HRMS (ESI-TOF) *m*/*z*: [M + Na]<sup>+</sup> calcd for C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>O<sub>6</sub>Na, 329.0745; found, 329.0748. The er was determined by HPLC using a Chiralpak IC column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 19:5 min,  $\tau_{minor}$  = 18.1 min (98:2 er). [ $\alpha$ ]<sup>20</sup><sub>2</sub> – 151.2 (*c* = 0.9, CHCl<sub>3</sub>).

(*R*,*E*)-*Methyl 3-((3-Methyl-4-nitroisoxazol-5-yl)methyl)-2-methylenehex-4-enoate (3k). Following the general procedure, 3k was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 84% yield (25.5 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>): \delta 6.23 (d, <i>J* = 0.7 Hz, 1H), 5.64 (t, *J* = 0.8 Hz, 1H), 5.57–5.46 (m, 2H), 3.80–3.77 (m, 1H), 3.77 (s, 3H), 3.49 (dd, *J* = 7.6, 2.6 Hz, 2H), 2.54 (s, 3H), 1.63 (d, 3H, *J* = 4.5 Hz,). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.4, 166.4, 155.8, 153.1, 142.5, 139.4, 127.8, 110.7, 107.2, 52.5, 38.3, 31.2, 11.9. HRMS (ESI-TOF) *m/z*: [M + Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>Na, 303.0952; found, 303.0947. The er was determined by HPLC using a Chiralpak IC column [hexane/iPrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major} = 6.7$  min,  $\tau_{minor} = 7.6$  min (95:5 er). [ $\alpha$ ]<sub>20</sub><sup>20</sup> –152.6 (*c* = 0.8, CHCl<sub>3</sub>).

(*R*)-Ethyl 4-(3-Methyl-4-nitroisoxazol-5-yl)-2-methylene-3-phenylbutanoate (31). Following the general procedure, 31 was isolated by FC on silica (hexane/ethyl acetate 96:4) in an 85% yield (30.0 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.29–7.26 (m, 2H), 7.23–7.21 (m, 3H), 6.39 (s, 1H), 5.74 (d, *J* = 1.2 Hz, 1H), 4.59–4.56 (m, 1H), 4.16–4.10 (m, 2H), 3.77 (d, *J* = 8.1 Hz, 2H), 2.50 (s, 3H), 1.21 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.9, 166.1, 155.6, 141.8, 140.1, 129.6, 128.8 (2C), 127.8 (2C), 127.5, 125.5, 61.2, 44.1, 32.4, 32.1, 14.2. HRMS (ESI-TOF) *m*/ *z*:  $[M + Na]^+$  calcd for  $C_{17}H_{18}N_2O_5Na$ , 353.1108; found, 353.1112. The er was determined by HPLC using a Chiralpak IG column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major} = 6.7$  min,  $\tau_{minor} = 7.5$  min (98:2 er).  $[\alpha]_D^{20} - 186.1$  (c = 0.8, CHCl<sub>3</sub>).

(*R*)-tert-Butyl 4-(3-Methyl-4-nitroisoxazol-5-yl)-2-methylene-3phenylbutanoate (3m). Following the general procedure, 3m was isolated by FC on silica (hexane/ethyl acetate 96:4) in a 90% yield (34.3 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.29– 7.26 (m, 2H), 7.22–7.19 (m, 3H), 6.30 (t, *J* = 0.7 Hz, 1H), 5.64 (dd, *J* = 1.4, 0.6 Hz, 1H), 4.51 (t, *J* = 8.1 Hz, 1H), 3.74 (dd, *J* = 8.1, 0.6 Hz, 2H), 2.50 (s, 3H), 1.35 (s, 9H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  173.0, 165.3, 155.6, 143.2, 140.4, 128.7 (3C), 127.8 (2C), 127.4, 124.7, 81.6, 44.2, 32.5, 28.0 (3C), 11.8. HRMS (ESI-TOF) *m/z*: [M + Na]<sup>+</sup> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>Na, 381.1421; found, 381.1427. The er was determined by HPLC using a Chiralpak IG column [hexane/ *i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 6.0 min,  $\tau_{minor}$  = 7.6 min (99:1 er). [ $\alpha$ ]<sup>20</sup><sub>D</sub> -197.1 (*c* = 0.9, CHCl<sub>3</sub>).

Procedure for the Synthesis of Compound 4a. An ordinary screwcap vial was charged with a magnetic stir bar and compound 3a (0.1 mmol) and treated with a freshly made 5 M aqueous solution of NaOH (0.1 mL, 5 equiv, 0.5 mmol). The resulting solution was heated at 60 °C in an oil bath for 2 h and then allowed to reach room temperature. Isolation of free carboxylic acid involved the following: cooling the aqueous solution of compound sodium salt, adjustment of pH to 3, and extraction with EtOAc  $(2 \times 5 \text{ mL})$ . Combined organic layers were dried over anhydrous MgSO4. The solvent was removed under reduced pressure. The crude mixture was dissolved in MeOH (3 mL) and cooled to 0 °C. Thionyl chloride (0.1 mL) was added dropwise, and the resulting solution was stirred overnight, allowing to warm gradually to room temperature. The solvent was removed under reduced pressure, and the crude mixture was diluted with EtOAc (10 mL) and washed with a saturated aqueous solution of NaHCO<sub>3</sub> (2  $\times$ 5 mL) and brine  $(2 \times 5 \text{ mL})$ . The organic layer was dried over anhydrous MgSO4 and the solvent removed under reduced pressure.

(*R*)-Dimethyl 2-Methylene-3-phenylpentanedioate (4a). Following the general procedure, pure product 4a was isolated by FC on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2) in an 83% yield (22.5 mg) as a paleyellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.28 (t, *J* = 7.6 Hz, 2H), 7.24–7.22 (m, 2H), 7.22–7.18 (m, 1H), 6.33 (s, 1H), 5.66 (d, *J* = 1.2 Hz, 1H), 4.45 (t, *J* = 7.8 Hz, 1H), 3.68 (s, 3H), 3.61 (s, 3H), 2.93 (dd, *J* = 15.6, 7.9 Hz, 1H), 2.81 (dd, *J* = 15.6, 7.9 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  172.0, 166.9, 142.5, 141.3, 128.6 (2C), 128.0 (2C), 127.1, 124.8, 52.1, 51.9, 42.9, 39.5. HRMS (ESI-TOF) *m/z*: [M + Na]<sup>+</sup> calcd for C<sub>14</sub>H<sub>16</sub>O<sub>4</sub>Na, 271.0941; found, 271.0949. The er was determined by HPLC using a Chiralpak IC column [hexane/*i*PrOH (90:10)]; flow rate 1.0 mL/min;  $\tau_{major}$  = 12.8 min,  $\tau_{minor}$  = 11.6 min (94:6 er). [ $\alpha$ ]<sub>20</sub><sup>20</sup> –149.4 (*c* = 0.8, CHCl<sub>3</sub>).

Procedure for the Synthesis of Compound **6a**. To the solution of **3a** (87.6 mg, 0.1 mmol, 1.0 equiv) in acetic acid (1.6 mL) was added zinc dust (101.4 mg, 1.6 mmol, 16 equiv) slowly. After 2 h at room temperature, the mixture was filtered over Celite, diluted with ethyl acetate (5 mL), and then washed with sodium bicarbonate solution ( $2 \times 5 \text{ mL}$ ). The combined organic phase was dried over MgSO<sub>4</sub> and concentrated in vacuo.

(*R*)-*Methyl* 4-(4-*Amino-3-methylisoxazol-5-yl*)-2-*methylene-3-phenylbutanoate* (6*a*). Following the general procedure, pure product 6*a* was isolated by FC on silica gel (hexane/ethyl acetate gradient from 3:1 to 1:1) in an 81% yield (23.3 mg) as a pale-yellow oil. <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>):  $\delta$  7.47–7.02 (m, 5H), 6.34 (s, 1H), 5.75 (s, 1H), 4.29 (t, *J* = 8.0 Hz, 1H), 3.66 (s, 3H), 3.28 (dd, *J* = 14.7, 6.7 Hz, 1H), 3.08 (dd, *J* = 14.7, 9.1 Hz, 1H), 2.12 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (176 MHz, CDCl<sub>3</sub>):  $\delta$  167.1, 155.2, 155.0, 142.3, 141.3, 128.7 (2C), 128.0 (2C), 127.2, 125.3, 121.9, 52.1, 45.3, 30.6, 9.4. HRMS (ESI-TOF) *m/z*: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub>, 287.1391; found, 287.1392. The er was determined by HPLC using a Chiralpak IA column [hexane/*i*PrOH (80:20)]; flow rate 1.0 mL/min;  $\tau_{major} = 5.2$  min,  $\tau_{minor} = 4.7$  min (94:6 er). [ $\alpha$ ]<sup>20</sup><sub>2</sub> -127.2 (*c* = 0.9, CHCl<sub>3</sub>).

# ASSOCIATED CONTENT

## **③** Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.9b02530.

A full account of screening results, additional scope studies, details of absolute configuration assignments (computational details), copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra, and HPLC chromatograms (PDF)

#### AUTHOR INFORMATION

# **Corresponding Author**

Łukasz Albrecht – Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, 90-924 Łódź, Poland; ⊚ orcid.org/0000-0002-4669-7670; Email: lukasz.albrecht@p.lodz.pl

#### Authors

- **Dorota Kowalczyk-Dworak** Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, 90-924 Łódź, Poland
- Marcin Kwit Department of Chemistry, Adam Mickiewicz University, 61-614 Poznań, Poland; orcid.org/0000-0002-7830-4560

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.9b02530

#### Author Contributions

All authors have given approval to the final version of the manuscript.

#### Notes

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

This project was realized within the Sonata Bis program (2015/18/E/ST5/00309) from the National Science Centre, Poland. All calculations were performed in Poznań Supercomputing and Networking Center.

#### REFERENCES

(1) (a) Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H. Comprehensive Asymmetric Catalysis; Springer: Berlin, 1999. (b) Mikami, K.; Lautens, M. New Frontiers in Asymmetric Catalysis; Wiley-Interscience: NJ, 2007.

(2) Badea, G.-I.; Radu, G. L. Carboxylic Acid - Key Role in Life Sciences; Intech Open, 2018.

(3) For examples, see: (a) Chinchilla, R.; Galindo, N.; Nájera, C. Dimethyl 2-(tosylmethyl) fumarate: An allyl sulfone as electrophilic reagent for the synthesis of itaconate ester derivatives. Tetrahedron 1996, 52, 1035. (b) Pierik, A. J.; Ciceri, D.; Bröker, G.; Edwards, C. H.; McFarlane, W.; Winter, J.; Buckel, W.; Golding, B. T. Rotation of the exo-methylene group of (R)-3-methylitaconate catalyzed by coenzyme B12-dependent 2-methyleneglutarate mutase from Eubacteriumbarkeri. J. Am. Chem. Soc. 2002, 124, 14039. (c) Nishimura, H.; Murayama, K.; Watanabe, T.; Honda, Y.; Watanabe, T. Absolute configuration of ceriporic acids, the iron redox-silencing metabolites produced by a selective lignin-degrading fungus. Chem. Phys. Lipids 2009, 159, 77. (d) Nakahashi, A.; Miura, N.; Monde, K.; Tsukamoto, S. Stereochemical studies of hexylitaconic acid, an inhibitor of p53-HDM2 interaction. Bioorg. Med. Chem. Lett. 2009, 19, 3027. (e) Steward, K. M.; Corbett, M. T.; Goodman, C. G.; Johnson, J. S. Asymmetric synthesis of diverse glycolic acid scaffolds via dynamic kinetic resolution of α-ketoesters. J. Am. Chem. Soc. 2012, 134, 20197.

(4) For a review, see: Liu, T.-Y.; Xie, M.; Chen, Y.-C. Organocatalytic asymmetric transformations of modified Morita-Baylis-Hillman adducts. *Chem. Soc. Rev.* **2012**, *41*, 4101.

(5) For selected applications of vinylogous reactants in allylic alkylation with MBH carbonates, see: (a) Cui, H.-L.; Peng, J.; Feng, X.; Du, W.; Jiang, K.; Chen, Y.-C. Dual organocatalysis: asymmetric allylic-allylic alkylation of  $\alpha_{,\alpha}$ -dicyanoalkenes and Morita-Baylis-Hillman carbonates. Chem. - Eur. J. 2009, 15, 1574. (b) Feng, J.; Li, X.; Cheng, J.-P. An asymmetric allylic alkylation reaction of 3alkylidene oxindoles. Chem. Commun. 2015, 51, 14342. (c) Zhao, S.; Zhao, Y.-Y.; Lin, J.-B.; Xie, T.; Liang, Y.-M.; Xu, P.-F. Organocatalyzed asymmetric vinylogous allylic-allylic alkylation of Morita-Baylis-Hillman carbonates with olefinicazlactones: facile access to chiral multifunctional  $\alpha$ -amino acid derivatives. Org. Lett. 2015, 17, 3206. (d) Kayal, S.; Mukherjee, S. Catalytic enantioselective vinylogous allylic alkylation of coumarins. Org. Lett. 2017, 19, 4944. (6) For selected reviews, see: (a) Fuson, R. C. The Principleof Vinylogy. Chem. Rev. 1935, 16, 1. (b) Pansare, S. V.; Paul, E. K. The organocatalytic vinylogous aldol reaction: recent advances. Chem. -Eur. J. 2011, 17, 8770. (c) Schneider, C.; Abels, F. Catalytic, enantioselective vinylogous Michael reactions. Org. Biomol. Chem. 2014, 12, 3531. (d) Hepburn, H. B.; Dell'Amico, L.; Melchiorre, P. Enantioselective vinylogous organocascade reactions. Chem. Rec. 2016, 16, 1787. (e) Battistini, L.; Curti, C.; Rassu, G.; Sartori, A.; Zanardi, F. Enolizable alkylidene heterocyclic and carbocyclic carbonyl systems: valuable vinylogous donor substrates in synthesis. Synthesis 2017, 49, 2297. (f) Chauhan, P.; Kaya, U.; Enders, D. Advances in organocatalytic 1,6-addition reactions: enantioselective construction of remote stereogenic centers. Adv. Synth. Catal. 2017, 359, 888. (g) Li, H.; Yin, L. Recent progress on direct catalytic asymmetric vinylogous reactions. Tetrahedron Lett. 2018, 59, 4121.

(7) For selected, recent examples, see: (a) Romaniszyn, M.; Gronowska, K.; Albrecht, Ł. 2-Substituted 1,4-naphthoquinones in [6 + 4]-cycloaddition with 8,8-dicyanoheptafulvene. J. Org. Chem. 2019, 84, 9929. (b) Skrzyńska, A.; Drelich, P.; Frankowski, S.; Albrecht, Ł. Synthesis of  $\gamma,\gamma$ -disubstituted butenolides through a doubly vinylogous organocatalytic cycloaddition. Chem. - Eur. J. 2018, 24, 16543. (c) Kowalczyk, D.; Albrecht, Ł. Vinylogous nucleophiles bearing the endocyclic double bond in the allylic alkylation with Morita-Baylis-Hillman carbonates. Adv. Synth. Catal. 2018, 360, 406. (d) Skrzyńska, A.; Romaniszyn, M.; Pomikło, D.; Albrecht, Ł. The application of 2-benzyl-1,4-naphthoquinones as pronucleophiles in aminocatalytic synthesis of tricyclic derivatives. J. Org. Chem. 2018, 83, 5019. (e) Przydacz, A.; Kowalczyk, R.; Albrecht, Ł. Brønsted-basecatalyzed remote cascade reactivity of 2,4-dienones-asymmetric synthesis of tetrahydrothiophenes. Org. Biomol. Chem. 2017, 15, 9566. (f) Hejmanowska, J.; Jasinski, M.; Wojciechowski, J.; Mloston, G.; Albrecht, Łu. The first organocatalytic, ortho-regioselective inverse-electron-demand hetero-Diels-Alder reaction. Chem. Commun. 2017, 53, 11472.

(8) For selected examples, see: (a) Adamo, M. F. A.; Nagabelli, M. Synthesis of homochiral dihydroxy-4-nitroisoxazolines via one-pot asymmetric dihydroxylation-reduction. Org. Lett. 2008, 10, 1807. (b) Baschieri, A.; Bernardi, L.; Ricci, A.; Suresh, S.; Adamo, M. F. A. Catalytic asymmetric conjugate addition of nitroalkanes to 4-nitro-5styrylisoxazoles. Angew. Chem., Int. Ed. 2009, 48, 9342. (c) Zhang, J.; Liu, X.; Ma, X.; Wang, R. Organocatalyzed asymmetric vinylogous Michael addition of  $\alpha_{,\beta}$ -unsaturated  $\gamma$ -butyrolactam. Chem. Commun. 2013, 49, 9329. (d) Li, Y.; Lopez-Delgado, F. J.; Jørgensen, D. K. B.; Nielsen, R. P.; Jiang, H.; Jørgensen, K. A. Trienamine-mediated asymmetric [4 + 2]-cycloaddition of  $\alpha,\beta$ -unsaturated ester surrogates applying 4-nitro-5-styrylisoxazoles. Chem. Commun. 2014, 50, 15689. (e) Disetti, P.; Moccia, M.; Illera, D. S.; Suresh, S.; Adamo, M. F. A. Catalytic enantioselective addition of isocyanoacetate to 3-methyl-4nitro-5-styrylisoxazoles under phase transfer catalysis conditions. Org. Biomol. Chem. 2015, 13, 10609. (f) Zhang, Y.; Wei, B.; Lin, H.; Cui, W.; Zeng, X.; Fan, X. Organocatalyzed asymmetric vinylogous Michael reactions of 3,5-dialkyl-substituted 4-nitroisoxazoles: adirect method for the synthesis of chiral isoxazolederivatives. Adv. Synth.

Catal. 2015, 357, 1299. (g) Zhu, B.; Lee, R.; Yin, Y.; Li, F.; Coote, M. L.; Jiang, Z. Enantioselective vinylogous amination of 5-alkyl-4nitroisoxazoles with a dipeptide-based guanidiniumphase-transfer catalyst. Org. Lett. 2018, 20, 429. (h) Li, S.-W.; Du, Y.; Kang, Q. A chiral-at-metal asymmetric catalyzed vinylogous Michael addition of ortho-methyl aromatic nitro compounds for isoxazole derivative synthesis. Org. Chem. Front. 2019, 6, 2775.

(9) (a) Baidya, M.; Remennikov, G. Y.; Mayer, P.; Mayr, H.  $S_N2'$  versus  $S_N2$  reactivity: control of regioselectivity in conversions of Baylis–Hillman adducts. *Chem. - Eur. J.* **2010**, *16*, 1365. (b) Basavaiah, D.; Reddy, B. S.; Lingam, H. Baylis–Hillman acetates in carbocyclic synthesis: a convenient protocol for synthesis of densely substituted indenes. *Tetrahedron* **2013**, *69*, 1994. (c) Zheng, Y.; Wang, J.; Xia, P.-J.; Zhao, Q.-l.; Xiao, J.-A.; Xiang, H.-Y.; Chen, X.-Q.; Yang, H. Organocatalytic asymmetric allylic alkylation of Morita–Baylis–Hillman carbonates with diethyl 2-aminomalonate assisted by in situ protection. *J. Org. Chem.* **2017**, *82*, 12202. For a related study, see: (d) Trost, B. M.; Brennan, M. K. Palladium-catalyzed regio-and enantioselective allylic alkylation of bisallylic carbonates derived from Morita-Baylis-Hillman adducts. *Org. Lett.* **2007**, *9*, 3961.

(10) Gaussian 09; Gaussian, Inc.: Wallingford, CT, 2009.

(11) Baldwin, J. E.; Hoefle, G. A.; Lever, O. W., Jr.  $\alpha$ -Methoxyvinyllithium and related metalated enol ethers. Practical reagents for nucleophilic acylation. J. Am. Chem. Soc. 1974, 96, 7125. (12) (a) Yang, W.; Du, D.-M. Highly enantioselective Michael addition of nitroalkanes to chalcones using chiral squaramides as hydrogen bonding organocatalysts. Org. Lett. 2010, 12, 5450. (b) Vakulya, B.; Varga, S.; Csámpai, A.; Soós, T. Highly enantioselective conjugate addition of nitromethane to chalcones using bifunctional cinchona organocatalysts. Org. Lett. 2005, 7, 1967.